Concepedia

Biosimilars: Considerations for Payers.

James E. Smeeding, Daniel C. Malone, Monica Ramchandani, Bradley S. Stolshek, Larry Green, Philip J. Schneider

PubMed · 2019 · 37 citations · 28 references

Full text

Open access

Concepts

Abstract

Evaluating biosimilars requires payers to go beyond cost considerations: safety and efficacy, reliability of supply and logistics, and the impact of state laws on substitution and interchangeability must all be deliberated.

References

28

Innovation in the pharmaceutical industry: New estimates of R&D costs

Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen · Journal of Health Economics · 2016 · 3.2K citations

, , +15

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Kamyar Kalantar‐Zadeh · American Journal of Nephrology · 2017 · 1.1K citations · Full text

, , +17

Pure Red-Cell Aplasia and Epoetin Therapy

Charles L. Bennett, Stefano Luminari, Allen R. Nissenson et al. · New England Journal of Medicine · 2004 · 432 citations · Full text

, , +9

Key drivers for market penetration of biosimilars in Europe

C. Rémuzat, J Dorey, Olivier Cristeau et al. · Journal of Market Access & Health Policy · 2017 · 213 citations · Full text

, , +15

Developing the Nation's Biosimilars Program

Steven Kozlowski, Janet Woodcock, Karen Midthun et al. · New England Journal of Medicine · 2011 · 196 citations

, , +15